Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Appendiceal Neoplasms | 12 | 2025 | 37 | 2.930 |
Why?
|
| Circulating Tumor DNA | 5 | 2024 | 76 | 2.570 |
Why?
|
| Peritoneal Neoplasms | 14 | 2025 | 184 | 2.520 |
Why?
|
| Colorectal Neoplasms | 12 | 2025 | 1053 | 2.040 |
Why?
|
| Hyperthermia, Induced | 8 | 2024 | 75 | 1.460 |
Why?
|
| Rectal Neoplasms | 6 | 2025 | 132 | 1.150 |
Why?
|
| Colonic Neoplasms | 5 | 2024 | 579 | 1.140 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 1448 | 0.730 |
Why?
|
| Adenocarcinoma | 7 | 2024 | 1173 | 0.650 |
Why?
|
| Precision Medicine | 1 | 2024 | 455 | 0.610 |
Why?
|
| Cytoreduction Surgical Procedures | 13 | 2025 | 92 | 0.610 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2024 | 2544 | 0.610 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1659 | 0.580 |
Why?
|
| Fluorouracil | 3 | 2024 | 524 | 0.420 |
Why?
|
| Pancreatic Neoplasms | 3 | 2024 | 715 | 0.400 |
Why?
|
| Neoplasm Staging | 4 | 2024 | 2017 | 0.340 |
Why?
|
| Humans | 39 | 2025 | 93501 | 0.340 |
Why?
|
| Radiosurgery | 2 | 2024 | 317 | 0.320 |
Why?
|
| Liver Neoplasms | 3 | 2024 | 776 | 0.300 |
Why?
|
| Neoadjuvant Therapy | 4 | 2025 | 446 | 0.290 |
Why?
|
| Microsatellite Instability | 3 | 2024 | 64 | 0.280 |
Why?
|
| Mutation | 6 | 2024 | 4272 | 0.270 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 7061 | 0.270 |
Why?
|
| Male | 17 | 2025 | 44552 | 0.260 |
Why?
|
| Retrospective Studies | 12 | 2024 | 10163 | 0.260 |
Why?
|
| Female | 18 | 2025 | 48696 | 0.260 |
Why?
|
| Celecoxib | 2 | 2024 | 33 | 0.260 |
Why?
|
| Combined Modality Therapy | 7 | 2024 | 1723 | 0.260 |
Why?
|
| Middle Aged | 14 | 2025 | 27569 | 0.260 |
Why?
|
| Survival Rate | 7 | 2023 | 1948 | 0.250 |
Why?
|
| Adult | 13 | 2025 | 27918 | 0.240 |
Why?
|
| Aged | 10 | 2025 | 20430 | 0.240 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2024 | 33 | 0.220 |
Why?
|
| Watchful Waiting | 1 | 2025 | 70 | 0.220 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2024 | 35 | 0.210 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2024 | 76 | 0.210 |
Why?
|
| Patient Preference | 1 | 2025 | 125 | 0.210 |
Why?
|
| Phenylurea Compounds | 1 | 2024 | 97 | 0.200 |
Why?
|
| Quinolines | 1 | 2024 | 85 | 0.200 |
Why?
|
| Peritoneum | 4 | 2024 | 52 | 0.200 |
Why?
|
| Surgical Oncology | 1 | 2023 | 29 | 0.200 |
Why?
|
| Patient Participation | 1 | 2025 | 229 | 0.190 |
Why?
|
| Mutation, Missense | 1 | 2024 | 297 | 0.190 |
Why?
|
| Appendix | 1 | 2023 | 30 | 0.190 |
Why?
|
| Vaccines | 1 | 2024 | 84 | 0.190 |
Why?
|
| Cancer Vaccines | 1 | 2024 | 167 | 0.190 |
Why?
|
| Quality Assurance, Health Care | 1 | 2024 | 225 | 0.190 |
Why?
|
| Neuroendocrine Tumors | 1 | 2024 | 136 | 0.180 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 2302 | 0.180 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 204 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 304 | 0.180 |
Why?
|
| Germ-Line Mutation | 1 | 2024 | 381 | 0.170 |
Why?
|
| Research Design | 1 | 2025 | 616 | 0.170 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 64 | 0.170 |
Why?
|
| Palliative Care | 1 | 2023 | 269 | 0.170 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2021 | 72 | 0.170 |
Why?
|
| Disease-Free Survival | 4 | 2024 | 1170 | 0.170 |
Why?
|
| Delphi Technique | 3 | 2025 | 135 | 0.160 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 2364 | 0.160 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 554 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2025 | 438 | 0.160 |
Why?
|
| Mitoxantrone | 1 | 2020 | 65 | 0.160 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 1103 | 0.160 |
Why?
|
| Etoposide | 1 | 2020 | 204 | 0.150 |
Why?
|
| Cytarabine | 1 | 2020 | 216 | 0.150 |
Why?
|
| Leucovorin | 3 | 2024 | 200 | 0.150 |
Why?
|
| Consensus | 3 | 2025 | 368 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 1001 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 603 | 0.130 |
Why?
|
| Neoplasms | 2 | 2024 | 3169 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 1073 | 0.110 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 1133 | 0.110 |
Why?
|
| Myeloproliferative Disorders | 1 | 2016 | 146 | 0.100 |
Why?
|
| Organoplatinum Compounds | 2 | 2024 | 91 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 826 | 0.100 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 2023 | 18 | 0.100 |
Why?
|
| Neoplasm Grading | 2 | 2024 | 402 | 0.100 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2023 | 40 | 0.090 |
Why?
|
| Pyridines | 2 | 2024 | 303 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2024 | 512 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2024 | 4559 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2024 | 1729 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2024 | 876 | 0.070 |
Why?
|
| Recurrence | 2 | 2023 | 1190 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2025 | 1052 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2024 | 761 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2023 | 3054 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2024 | 9097 | 0.060 |
Why?
|
| Quality of Life | 2 | 2024 | 1780 | 0.060 |
Why?
|
| DNA Mismatch Repair | 1 | 2024 | 58 | 0.050 |
Why?
|
| Anilides | 1 | 2024 | 45 | 0.050 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2024 | 50 | 0.050 |
Why?
|
| Capecitabine | 1 | 2024 | 97 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2024 | 122 | 0.050 |
Why?
|
| Standard of Care | 1 | 2024 | 70 | 0.050 |
Why?
|
| Trifluridine | 1 | 2023 | 3 | 0.050 |
Why?
|
| Fatigue | 1 | 2024 | 181 | 0.050 |
Why?
|
| Diarrhea | 1 | 2024 | 179 | 0.050 |
Why?
|
| Advance Directives | 1 | 2023 | 64 | 0.050 |
Why?
|
| Organ Sparing Treatments | 1 | 2023 | 47 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2023 | 96 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 178 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2024 | 228 | 0.050 |
Why?
|
| Anal Canal | 1 | 2023 | 92 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 204 | 0.050 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2024 | 131 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2022 | 48 | 0.050 |
Why?
|
| Monoterpenes | 1 | 2022 | 6 | 0.050 |
Why?
|
| GPI-Linked Proteins | 1 | 2022 | 55 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2024 | 355 | 0.040 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2021 | 12 | 0.040 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2021 | 14 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 282 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2023 | 276 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2022 | 200 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 398 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2023 | 406 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 176 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2023 | 326 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 321 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2022 | 657 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 315 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 526 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 454 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2021 | 824 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 960 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1321 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1175 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 537 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 409 | 0.040 |
Why?
|
| Hypertension | 1 | 2024 | 757 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 1531 | 0.040 |
Why?
|
| Length of Stay | 1 | 2021 | 828 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2802 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1049 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 1910 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1740 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 2755 | 0.030 |
Why?
|
| Apoptosis | 1 | 2021 | 1721 | 0.030 |
Why?
|
| Prognosis | 1 | 2023 | 3910 | 0.030 |
Why?
|
| Illinois | 1 | 2016 | 520 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2021 | 3500 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2021 | 2562 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 6930 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 12263 | 0.020 |
Why?
|
| Animals | 1 | 2021 | 28148 | 0.010 |
Why?
|